RedHill Biopharma (RDHL) Net Income (2016 - 2023)
Historic Net Income for RedHill Biopharma (RDHL) over the last 12 years, with Q2 2023 value amounting to $58.9 million.
- RedHill Biopharma's Net Income rose 79179.66% to $58.9 million in Q2 2023 from the same period last year, while for Dec 2024 it was $58.9 million, marking a year-over-year increase of 41816.51%. This contributed to the annual value of -$14613.0 billion for FY2024, which is 6110142821.12% down from last year.
- RedHill Biopharma's Net Income amounted to $58.9 million in Q2 2023, which was up 79179.66% from -$7.9 million recorded in Q1 2023.
- RedHill Biopharma's Net Income's 5-year high stood at $58.9 million during Q2 2023, with a 5-year trough of -$145.2 million in Q4 2021.
- Over the past 5 years, RedHill Biopharma's median Net Income value was $11.1 million (recorded in 2019), while the average stood at -$1.3 million.
- As far as peak fluctuations go, RedHill Biopharma's Net Income tumbled by 106284.39% in 2021, and later surged by 79179.66% in 2023.
- Quarter analysis of 5 years shows RedHill Biopharma's Net Income stood at $11.8 million in 2019, then grew by 27.44% to $15.1 million in 2020, then tumbled by 1062.84% to -$145.2 million in 2021, then surged by 52.14% to -$69.5 million in 2022, then surged by 184.75% to $58.9 million in 2023.
- Its Net Income stands at $58.9 million for Q2 2023, versus -$7.9 million for Q1 2023 and -$69.5 million for Q4 2022.